Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ39758979 · 1 trial · 1 indication
FEV1 will be measured by using spirometry test. Spirometry is used to measure lung function, specifically the amount (volume) and/or speed (flow) of air that can be inhaled and exhaled. Lung volumes will be measured according to the body temperature, pressure, and saturated standard convention using the spirometer. Pre-bronchodilator spirometry will be performed in the absence of albuterol/salbutamol or at least 6 hours after the last dose of albuterol/salbutamol.
| Arm | Type | Description |
|---|---|---|
| Treatment A (JNJ39758979) | EXPERIMENTAL | Participants will receive JNJ39758979 300mg once daily for 12 weeks. |
| Treatment B (Placebo) | PLACEBO_COMPARATOR | Participants will receive matching placebo once daily for 12 weeks. |
| Name | Type | Description |
|---|---|---|
| JNJ39758979 | DRUG | Participants will receive capsule-shaped tablet of JNJ39758979 300mg once daily orally for 12 weeks. |
| Placebo | DRUG | Participants will receive matching placebo once daily orally for 12 weeks. |
Inclusion Criteria: * Confirmed diagnosis of asthma for at least 6 months * Short-acting beta-agonist use greater than or equal to 5 times in the 2 weeks prior to screening * Healthy on the basis of physical examination, medical history, vital signs, and 12 lead ECG performed at screening * Having ...
JNJ-39758979 is an investigational small molecule being studied for the treatment of asthma and rheumatoid arthritis. It is being developed by Johnson & Johnson (JNJ) and has been evaluated in clinical trials for these conditions.
JNJ-39758979 is being developed by Johnson & Johnson, which trades on the New York Stock Exchange under the ticker JNJ. The company has sponsored clinical trials of the drug in asthma and rheumatoid arthritis.
JNJ-39758979 is an investigational drug that has completed clinical trials. One trial was a Phase 2 study in asthma, and another was a Phase 1 study in rheumatoid arthritis. It is not approved and remains in clinical development.
JNJ-39758979 has been studied in two completed trials. NCT00946569 was a Phase 2 study in adults with persistent asthma, enrolling 116 participants in the United States, Canada, India, and Romania. NCT01442545 was a Phase 1 study in rheumatoid arthritis participants, enrolling 21 participants in the United States and Germany.
JNJ-39758979 is not the same as MTX, which is methotrexate. In a clinical trial, JNJ-39758979 was studied to investigate how it may affect the plasma levels of methotrexate in rheumatoid arthritis participants, indicating the two are distinct drugs.